BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Velcade bortezomib: Phase II data

A Phase II trial in 35 previously untreated patients with DLBCL showed that Velcade plus R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) led to an ORR of 100%, with a complete response rate of 86%. At a median follow-up of 51 months, 2-year PFS and OS were 64% and 70%, respectively, while median PFS and OS have not yet...

Read the full 280 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >